Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 12/20 | 0.34 |
| ▸ | MMP3 | P08254 | 10/20 | 0.34 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58029 | 1.00 | TUBB1 (0.61) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL58793 | 0.92 | TUBB1 (0.60) | TUBB1MMP2MMP3MMP1 | |
| SCHEMBL13682035 | 0.92 | TUBB1 (0.60) | TUBB1MMP2MMP3MMP1 | |
| SCHEMBL6670635 | 0.91 | TUBB1 (0.58) | TUBB1MMP2MMP3 | |
| SCHEMBL6670504 | 0.90 | TUBB1 (0.62) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL6674531 | 0.90 | TUBB1 (0.60) | TUBB1MMP2MMP3MMP1 | |
| SCHEMBL6674523 | 0.90 | TUBB1 (0.60) | TUBB1MMP2MMP3MMP1 | |
| SCHEMBL89154 | 0.90 | TUBB1 (0.53) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL58323 | 0.90 | TUBB1 (0.53) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL14568138 | 0.90 | TUBB1 (0.53) | TUBB1MMP2MMP3MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | TUBB1 1157/4885MMP2 1161/4885MMP3 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.